Ranbaxy posts cons net loss at Rs 465 cr in Q3

40048 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy posts cons net loss at Rs 465 cr in Q3

Pharmaceutical firm Ranbaxy Labs has reported a consolidated net loss of Rs 465 crore in the third quarter of 2011 as against Rs 308 crore in the corresponding quarter of last fiscal. The loss was due to the forex loss of Rs 400 crore in the quarter.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ News and Notices about Ranbaxy Labs See interviews with Ranbaxy Labs Management See what other Experts & Brokerages are saying about Ranbaxy Labs See previous Results of Ranbaxy Labs

Pharmaceutical firm Ranbaxy Labs has reported a consolidated net loss of Rs 465 crore in the third quarter of 2011 as against Rs 308 crore in the corresponding quarter of last fiscal. The loss was due to the forex loss of Rs 400 crore in the quarter.

Additional loss arising out of derivatives MTM stood at Rs 251 crore during the same period.

Net sales moved up 7.7% to Rs 2,022 crore in the July-September quarter of 2011 versus Rs 1,877 crore in a year ago period.

EBITDA margins improved at 8.3% versus 7.2%, which included other operating income.